F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B

This publication has 12 references indexed in Scilit:

• Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study
  Haematologica, 2020
• Inhibitors in Hemophilia B
  Seminars in Thrombosis and Hemostasis, 2018
• Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
  Genetics in Medicine, 2015
• The intron-22–inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics
  Blood, 2015
• The CDC Hemophilia B mutation project mutation list: a new online resource
  Molecular Genetics & Genomic Medicine, 2013
• Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B
  Thrombosis and Haemostasis, 2013
• γ-Glutamate and β–Hydroxyaspartate in Proteins
  2007
• Structure–Function Relationships in Factor IX and Factor IXa
  Trends in Cardiovascular Medicine, 2003
• Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B
  Blood, 2001
• The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability
  Thrombosis and Haemostasis, 1995